Xadago - (50 mg and 100 mg; Tablet)

Generic Name	Safinamide Mesylate	Innovator	NEWRON PHARMACEUTICALS (MDD US OPERATIONS LLC)
Dosage	50 mg and 100 mg; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	Less Than 5
Final Approvals	Less Than 5	Generic Launches	None
Indication	Xadago is a type of prescription medicine known as monoamine oxidase type B (MAO-B) inhibitor used with levodopa and carbidopa to treat adults with Parkinson's disease (PD)
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** \ ***	*** **, ****	*******	******** ************	******* *** **** *** *** ****
*** ****	*** \ *********	*** **, ****	*******	****	******* *** **** *** *** ****
******* ******	*** \ **	*** **, ****	********* ** **** ***	********* ********	***** *** **, ****

Chronology Of Events